Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979661 · ClinicalTrials.gov registry record · Early Phase 1
Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy
A Early Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
NCT06979661: Clinical Trial Early Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
NCT06979661 is a Early Phase 1 study that has not yet begun recruiting, run by Rutgers, The State University of New Jersey. The registered enrollment target is 25 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06979661, a Early Phase 1 study, has not yet begun recruiting, sponsored by Rutgers, The State University of New Jersey.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Primary Objective: Evaluate the role of ctDNA positivity in decision making for postoperative therapy for non-small cell lung cancer. The plan for postoperative therapy will be declared after pathology report review and before the ctDNA result. We will assess if ctDNA result changed the planned therapy. Secondary Objectives: Evaluate personalized postoperative Chemo/ICPI/Targeted Therapies/Radiation Therapy in clearing ctDNA Evaluate the disease-free survival (DFS) and overall survival (OS) of stage II/III lung cancer patients with postoperative ctDNA positive status Exploratory Objective: Evaluate radiomics features based on serial CT thoracic CT scans to determine if radiomic features can be associated with ctDNA positivity/negativity.
Primary Outcome
This outcome will assess the presence or absence of circulating tumor DNA (ctDNA) in blood samples collected at multiple time points following surgical resection of Stage II-III non-small cell lung cancer (NSCLC). The Haystack™ ctDNA assay will be used to detect minimal residual disease (MRD), and results will be evaluated for their ability to predict recurrence and guide postoperative radiation and systemic therapy decisions.
Interventions
- DIAGNOSTIC_TEST Haystack™ ctDNA Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2029-06-01 |
| Phase | Early Phase 1 |
What is known before NCT06979661 opens enrollment
NCT06979661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which Haystack™ ctDNA Assay is the first listed.
NCT06979661 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06979661 about?
NCT06979661 is a clinical study titled "Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy". Primary Objective: Evaluate the role of ctDNA positivity in decision making for postoperative therapy for non-small cell lung cancer. The plan for postoperative therapy will be declared after pathology report review and before the ctDNA result. We will assess if ctDNA result changed the planned the...
What is the current status of trial NCT06979661?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2025-06-01. Estimated completion is 2029-06-01.
What interventions are being tested in trial NCT06979661?
The interventions under investigation include: Haystack™ ctDNA Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06979661?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06979661's enrollment target sits among peer trials
25 1000th of 2000 higher than 964 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI